Infectious Disease Clinical Trials

Statistical methods in infectious disease trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All infectious disease trials

609 results

• BAY 0 9867 Cipro Pediatric Use Study (QUIP): Complete Statistical AnalysisIndependent statistical analysis of BAY 0 9867 Cipro Pediatric Use Study (QUIP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00761462).Phase 3Results postedn = 1,029NCT00761462
• BE HEARD IIIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 509NCT04242498
• BEe-HIVeIndependent statistical analysis of B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 638NCT04193189
• Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine: Complete Statistical AnalysisIndependent statistical analysis of Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04538040).Phase 4Results postedn = 20NCT04538040
• BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05087524).Phase NAResults postedn = 65NCT05087524
• Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men: Complete Statistical AnalysisIndependent statistical analysis of Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 170NCT01140880
• Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 42NCT00682630
• BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent: Complete Statistical AnalysisIndependent statistical analysis of BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 17NCT02068846
• BLAZE-2Complete statistical analysis of BLAZE-2, a randomized phase 3 trial evaluating bamlanivimab for prevention of COVID-19 in nursing home residents and staff, including trial design, endpoints, logistic regression methodology, reported results, and…Phase 3Results postedn = 1,180NCT04497987
• Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts: Complete Statistical AnalysisIndependent statistical analysis of Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 16NCT03160079
• Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 669NCT02101853
• BLIR-HIVIndependent statistical analysis of Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01228318).Phase 2Results postedn = 63NCT01228318
• Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen: Complete Statistical AnalysisIndependent statistical analysis of Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen: primary endpoint results, effect estimate…Phase 3Results postedn = 102NCT02478632
• Booster Dose Trial: Complete Statistical AnalysisIndependent statistical analysis of Booster Dose Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05016622).Phase 2Results postedn = 106NCT05016622
• Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 305NCT00463476
• Brief Educational Video for Patients Prescribed LTBI Treatment: Complete Statistical AnalysisIndependent statistical analysis of Brief Educational Video for Patients Prescribed LTBI Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05412212).Phase NAResults postedn = 1,894NCT05412212
• Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis: Complete Statistical AnalysisIndependent statistical analysis of Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 19NCT01955980
• C_ASCENTIndependent statistical analysis of Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 46NCT02194998
• C3Independent statistical analysis of Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 1,328NCT04743908
• cAd3-Marburg Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of cAd3-Marburg Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03475056).Phase 1Results postedn = 40NCT03475056
• CAN-COVIDIndependent statistical analysis of CAN-COVID, a randomized phase 3 study of canakinumab versus placebo for cytokine release syndrome in participants with COVID-19-induced pneumonia, including its primary binary endpoint, logistic regression, odds ratio,…Phase 3Results postedn = 454NCT04362813
• Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL: Complete Statistical AnalysisIndependent statistical analysis of Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL: primary endpoint results, effect…Phase 2Results postedn = 170NCT02212379
• CAPICAIndependent statistical analysis of Chlorhexidine-Alcohol Versus Povidone-Iodine for Cesarean Antisepsis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02202577).Phase NAResults postedn = 932NCT02202577
• CAPRISA 004Independent statistical analysis of CAPRISA 004, a randomized phase 2 study of tenofovir gel versus placebo for prevention of HIV infection, including trial design, endpoint methodology, planned analysis, and statistical interpretation.Phase 2n = 889NCT00441298
• Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors – Effect of Fenofibrate: Complete Statistical AnalysisIndependent statistical analysis of Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 12NCT05080192
• CARDSIndependent statistical analysis of Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04427280).Phase NAResults postedn = 153NCT04427280
• CareConekta: A Smartphone App to Improve Engagement in HIV Care: Complete Statistical AnalysisIndependent statistical analysis of CareConekta: A Smartphone App to Improve Engagement in HIV Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03836625).Phase NAResults postedn = 200NCT03836625
• CATCH-UPIndependent statistical analysis of Community-engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 323NCT04870307
• CATCH-UP Vaccines: Engaged Approaches to Testing in Community/Healthcare Settings for the Underserved (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of CATCH-UP Vaccines: Engaged Approaches to Testing in Community/Healthcare Settings for the Underserved (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 312NCT05236270
• Causes of Rotavirus Vaccine Failure in Zambian Children: Complete Statistical AnalysisIndependent statistical analysis of Causes of Rotavirus Vaccine Failure in Zambian Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01886833).Phase NAResults postedn = 420NCT01886833
• CCBCRISIS04Independent statistical analysis of Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 26NCT05166876
• CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements: Complete Statistical AnalysisIndependent statistical analysis of CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase EARLY_1Results postedn = 8NCT01313910
• CDI-SCOPEIndependent statistical analysis of A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection: primary endpoint results, effect estimate with…Phase 3Results postedn = 41NCT05831189
• CENSERIndependent statistical analysis of CENSER (NCT01945983), a randomized trial evaluating early norepinephrine in septic shock resuscitation, including design, endpoints, planned analysis, and statistical interpretation.Phase NAn = 310NCT01945983
• Cerebrospinal Fluid (CSF) Pharmacokinetics of Antimicrobials in Children: Complete Statistical AnalysisIndependent statistical analysis of Cerebrospinal Fluid (CSF) Pharmacokinetics of Antimicrobials in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00991185).Phase NAResults postedn = 8NCT00991185
• CERTAIN-2Independent statistical analysis of A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection: primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 136NCT02723084
• CHANGEIndependent statistical analysis of "CHANGE COVID-19 Severity": primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04941703).Phase 1/2Results postedn = 23NCT04941703
• Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir: Complete Statistical AnalysisIndependent statistical analysis of Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 11NCT02097108
• Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa: Complete Statistical AnalysisIndependent statistical analysis of Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 1,250NCT00346476
• CHPIndependent statistical analysis of Couples Health Project: Couples-based Intervention to Reduce Drug Use and HIV Transmission Risk: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 100NCT03386110
• CJC-TraCIndependent statistical analysis of Criminal Justice Coordinated Transitional Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05376371).Phase NAResults postedn = 219NCT05376371
• Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 17NCT04348500
• CLEVERIndependent statistical analysis of Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04767373).Phase 2/3Results postedn = 3,632NCT04767373
• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis: Complete Statistical AnalysisIndependent statistical analysis of Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 136NCT01740388
• Clinical Efficacy Evaluation of Three Dentifrices: Complete Statistical AnalysisIndependent statistical analysis of Clinical Efficacy Evaluation of Three Dentifrices: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03988374).Phase 2Results postedn = 319NCT03988374
• Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis: Complete Statistical AnalysisIndependent statistical analysis of Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1Results postedn = 548NCT00835510
• Clinical Investigation Study to Evaluate the Consistency and Reproducibility of Two Consecutive Mosquito Feeding Assays: Complete Statistical AnalysisIndependent statistical analysis of Clinical Investigation Study to Evaluate the Consistency and Reproducibility of Two Consecutive Mosquito Feeding Assays: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 42NCT04666350
• Clinical Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) Utilizing Vaginal Swabs: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) Utilizing Vaginal Swabs: primary endpoint…Phase NAResults postedn = 295NCT03596151
• Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 435NCT04918771
• Clinical Study of the Immunogenicity of GSK Biologicals’ Influenza Vaccine GSK2186877A in People Aged 65 Years or Older: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 192NCT00765076

← All therapeutic areas